Detalhe da pesquisa
1.
Telehealth during COVID-19 restrictions in patients with cardiovascular disease: impact on medication prescriptions and patient satisfaction.
Intern Med J;
2024 Mar 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38506546
2.
Barriers to prescribing proprotein convertase subtilisin-kexin type 9 inhibitors after coronary revascularisation.
Intern Med J;
53(6): 994-1001, 2023 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35112773
3.
Investigating the effect of an education programme on diabetes and lipid lowering medication usage following coronary artery bypass graft surgery.
Intern Med J;
52(8): 1354-1365, 2022 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34033208
4.
Managing inpatient hyperglycaemia and initiating sodium-glucose cotransporter 2 inhibitor therapy in the setting of diabetes and acute coronary syndrome.
Intern Med J;
51(3): 428-432, 2021 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33738945
5.
Priorities and practicalities of prescribing diabetes medicines with cardiovascular and renal protective effects: an Australian perspective.
Intern Med J;
50(11): 1423-1429, 2020 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33215837
6.
Real-world barriers and safety of initiating sodium-glucose co-transporter 2 inhibitor treatment immediately following an acute cardiac event in people with diabetes.
J Diabetes Complications;
35(12): 108057, 2021 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34610888
7.
The role of a Coronavirus disease 2019 pharmacist: an Australian perspective.
Int J Clin Pharm;
42(5): 1379-1384, 2020 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32472325
8.
Short-term outcomes following coronary artery bypass graft surgery in insulin treated and non-insulin treated diabetes: A tertiary hospital experience in Australia.
Diabetes Metab Syndr;
14(4): 455-458, 2020.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32371190